ScreenerHero

HBP Helix BioPharma Corp.

TSX · CA · Healthcare · Biotechnology · helixbiopharma.com
0.9200CAD-6.12%Mkt Cap: 51.17M $P/E: —

Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) th…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap51.17M USD
Enterprise Value49.37M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-2.42M USD
Revenue/Share—
Last Price0.9200 CAD
Fiscal Year EndJul 2025
MR QuarterApr 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.36
PEG—
EV/EBITDA-20.82
EV/Revenue—
P/S—
P/B4.79
EPS (TTM)-0.04
EPS (Forward)-0.11
52W Range
0.85002% of range5.400
52W High5.400 CAD
52W Low0.8500 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-49.99%
ROA-18.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.80M USD
CapEx (TTM)10.20K USD
FCF Margin—
FCF Yield2.90%
Net Debt-1.81M USD
Net Debt/EBITDA0.76
Balance Sheet
Debt/Equity2.45
Current Ratio0.45
Quick Ratio0.43
Book Value/Sh0.19 CAD
Cash/Share0.04 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CAD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateAug 16, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.76.38M
Float45.92M
Insiders28.95%
Institutions0.00%
Short Interest
Short Ratio0.3d
Short % Float0.00%
Short % Out.0.00%
Shares Short729
Short (prev mo.)365
Technical
SMA 501.552 (-40.7%)
SMA 2001.753 (-47.5%)
Beta-0.14
S&P 52W Chg16.45%
Avg Vol (30d)11.42K
Avg Vol (10d)28.96K
Technical Indicators
RSI (14)29.6
MACD-0.1895
MACD Signal-0.1559
MACD Hist.-0.0336
BB Upper1.852 CAD
BB Middle1.272 CAD
BB Lower0.6928 CAD
BB Width91.10%
ATR (14)0.1245 CAD
Vol Ratio (20d)0.03x